ERBB2 and breast cancer: In the MARIANNE trial enrolling pretreated patients with HER2-positive BC, the addition of pertuzumab to T-DM1 did not achieve a clinically significant OS benefit (51.8 vs 53.7 months) and the treatment related adverse event were similar between the two groups (48.6 vs 47.1%) [82].